Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
|Videos|May 8, 2017
Uncontrolled Polycythemia Vera: Case 1
Uncontrolled Polycythemia Vera
Advertisement
August 2014
- A 67-year-old female is diagnosed PV after complaining of fatigue
- Physical Exam was unremarkable
- CBC:
- HCT, 48%
- WBC, 12,100/μL
- Platelets, 603,000/μL
- Mutation testing: JAK2 V617F-positive
- The patient was started on treatment with low-dose aspirin and hydroxyurea 500 mg/day
- Her symptoms resolved within 3 months
February 2016
- She now complains of left upper quadrant pain
- For 1.5 years, the patient was maintained on treatment; however, for the past 9 months her hematocrit has risen to 48% and she has required 4 phlebotomies in last 6 months
- Hydroxyurea was increased from 500 mg to 1,000 mg daily
- Physical Exam: remarkable for splenomegaly
August 2016
- Physical Exam: still remarkable for splenomegaly, slightly smaller
- HCT 47.5%
Advertisement
Related to this article
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5